

# Contents

Foreword . . . . .	XV
Notes on the use of this book . . . . .	1
<b>Autoantibodies — Definitions and Characteristics</b> . . . . .	2
<b>Autoantibodies in the Diagnosis of Autoimmune Diseases</b> . . . . .	3

## Part 1

### Autoantibodies in organ specific autoimmune diseases

17 $\alpha$ -hydroxylase antibodies . . . . .	6
21-hydroxylase antibodies . . . . .	6
AADC antibodies . . . . .	6
Acetylcholine receptor antibodies, general . . . . .	6
Acetylcholine receptor antibodies, classical type . . . . .	7
Actin antibodies . . . . .	8
ADAMTS13 antibodies . . . . .	9
Adrenal cortex antibodies . . . . .	10
Adrenoceptor antibodies . . . . .	12
Alpha enolase antibodies . . . . .	12
Alveolar basement membrane antibodies . . . . .	13
AMA (anti-mitochondrial antibodies) . . . . .	14
AMA-M2 . . . . .	16
AMA-M4 . . . . .	19
AMA-M8 . . . . .	20
AMA-M9 . . . . .	21
AMPA receptor antibodies . . . . .	22
Amphiphysin antibodies . . . . .	22
Angiotensin 1 receptor antibodies . . . . .	24
ANNA-1 . . . . .	24
ANNA-2 . . . . .	24
ANNA-3 . . . . .	25

Anti-mitochondrial antibodies . . . . .	26
Anti-neuronal nuclear antibodies (ANNA) . . . . .	26
Anti-neutrophil cytoplasmic antibodies (ANCA) . . . . .	26
Anti-nuclear antibodies (ANA) . . . . .	27
Anti- <i>Saccharomyces cerevisiae</i> antibodies (ASCA) . . . . .	28
Aquaporin 4 antibodies . . . . .	30
Aromatic L-amino acid decarboxylase antibodies . . . . .	31
ASGPR antibodies . . . . .	32
Atypical ANCA . . . . .	34
Beta 1 adrenergic receptor antibodies . . . . .	34
Bithermal hemolysins . . . . .	35
BP180 antibodies . . . . .	35
BP230 antibodies . . . . .	35
C1 inhibitor antibodies . . . . .	36
C1q antibodies . . . . .	37
C3 nephritic factor . . . . .	38
C4 nephritic factor . . . . .	40
Calcium channel antibodies . . . . .	40
Calcium sensitive receptor antibodies . . . . .	42
CAR antibodies . . . . .	43
Carboanhydrase II antibodies . . . . .	44
Caspr2 antibodies . . . . .	45
Coagulation factor antibodies . . . . .	45
Cold antibodies . . . . .	46
Complement antibodies . . . . .	46
Collagen VII antibodies . . . . .	46
Colonic epithelial antibodies . . . . .	47
CV2/CRMP5 antibodies . . . . .	47
CYP antibodies . . . . .	49
Cytochrome P450 antibodies . . . . .	49
Cytochrome P450 side chain cleavage enzyme (P450scc) antibodies . . . . .	49
Desmoglein 1 antibodies . . . . .	50
Desmoglein 3 antibodies . . . . .	50
Dihydropyridine receptor antibodies . . . . .	50
Donath-Landsteiner antibodies . . . . .	51
Endomysium antibodies (EmA) . . . . .	51
Enterocyte antibodies . . . . .	53
Erythrocyte antibodies . . . . .	54
Factor VIII antibodies . . . . .	56
Factor B antibodies . . . . .	59
Factor H antibodies . . . . .	59
Fc $\epsilon$ RI antibodies . . . . .	59

---

Fc receptor antibodies . . . . .	60
Folate receptor antibodies . . . . .	60
GABA <sub>B</sub> receptor antibodies . . . . .	61
GAD antibodies . . . . .	61
Ganglionic nAChR antibodies . . . . .	63
Ganglioside antibodies . . . . .	65
Gephyrin antibodies . . . . .	69
Gliadin antibodies . . . . .	70
Glomerular basement membrane antibodies . . . . .	72
GluR3 antibodies . . . . .	74
Glutamate receptor antibodies . . . . .	75
Goblet cell antibodies (GAB) . . . . .	75
GOR antibodies . . . . .	78
gp210 antibodies . . . . .	79
GWB antibodies . . . . .	81
Heart muscle antibodies . . . . .	82
Heat shock protein antibodies . . . . .	83
H <sup>+</sup> /K <sup>+</sup> ATPase antibodies . . . . .	84
Hormone antibodies . . . . .	84
Hu antibodies (ANNA-1) . . . . .	85
IA2 antibodies . . . . .	87
Insulin antibodies . . . . .	89
Insulin receptor antibodies . . . . .	90
Intrinsic factor antibodies (IFA) . . . . .	91
Islet cell antibodies (ICA) . . . . .	93
LAD-1 antibodies . . . . .	95
Lamin antibodies . . . . .	95
Lamin B receptor antibodies . . . . .	96
LAMP-2 antibodies . . . . .	98
LC1 antibodies . . . . .	99
Leydig cell antibodies . . . . .	101
Lg11-antibodies . . . . .	102
LKM1-antibodies . . . . .	102
LKM2 antibodies . . . . .	105
LKM3 antibodies . . . . .	105
LM antibodies . . . . .	106
LP/SLA antibodies . . . . .	107
Ma1 antibodies . . . . .	107
Ma2 antibodies . . . . .	108
MAG antibodies . . . . .	110
Moesin antibodies . . . . .	111
MuSK antibodies . . . . .	111

NALP5 antibodies . . . . .	112
Neutrophil antibodies . . . . .	112
Neutrophil specific antibodies . . . . .	113
NMDA receptor antibodies . . . . .	114
Nuclear body antibodies . . . . .	116
Nuclear envelope antibodies . . . . .	117
Nucleoporin antibodies . . . . .	117
ONA antibodies . . . . .	118
Ovarian antibodies . . . . .	121
p62 antibodies . . . . .	121
p95C antibodies . . . . .	121
pANCA . . . . .	121
Pancreas acinar antibodies (PAb) . . . . .	123
Pancreas antibodies . . . . .	124
Paraneoplastic antibodies . . . . .	124
Parietal cell antibodies (PCA) . . . . .	124
PBCNA antibodies . . . . .	126
Pemphigus antibodies . . . . .	126
Pemphigoid antibodies . . . . .	128
Phospholipase A2 receptor antibodies . . . . .	131
Phospholipid antibodies . . . . .	131
PKCy antibodies . . . . .	133
PML antibodies . . . . .	133
Potassium channel antibodies . . . . .	134
Purkinje cell antibodies type 2 (PCA-2) . . . . .	136
Receptor antibodies . . . . .	137
Recoverin antibodies . . . . .	138
Reticulin antibodies . . . . .	138
Retina antibodies . . . . .	138
Ri antibodies . . . . .	140
Ryanodine receptor antibodies . . . . .	141
SLA/LP antibodies . . . . .	142
SMA . . . . .	144
SOX1 antibodies . . . . .	146
SOX13 antibodies . . . . .	147
Sp100 antibodies . . . . .	147
Spermatozoa antibodies . . . . .	149
Steroid producing cell antibodies . . . . .	151
SUMO antibodies . . . . .	153
Thrombocyte antibodies . . . . .	153
Thyroglobulin antibodies . . . . .	155
Thyroperoxidase antibodies . . . . .	157

---

Tissue transglutaminase antibodies (TTG) . . . . .	159
Titin antibodies . . . . .	162
Tr antibodies . . . . .	163
Trib2 antibodies . . . . .	164
Tropomyosin 5 antibodies . . . . .	164
Tryptophan hydroxylase (TPH) antibodies . . . . .	165
TSH receptor antibodies (TRAb) . . . . .	165
Tyrosinase antibodies . . . . .	167
Tyrosine hydroxylase (TH) antibodies . . . . .	168
Vasopressin producing cell antibodies . . . . .	168
VGCC antibodies . . . . .	169
VGPC antibodies . . . . .	169
Warm antibodies . . . . .	169
von Willebrand factor antibodies . . . . .	169
xANCA . . . . .	170
Yo antibodies . . . . .	170
Zic antibodies . . . . .	172
ZnT8 antibodies . . . . .	172

## **Part 2**

### **Organ specific autoimmune diseases – symptoms, entities, syndromes**

Achalasia . . . . .	174
Acquired angioedema type II . . . . .	174
Acute disseminated encephalomyelitis (ADEM) . . . . .	174
Acute inflammatory demyelinating polyneuropathy (AIDP) . . . . .	175
Acute motor axonal neuropathy (AMAN) . . . . .	175
Acute motor sensory axonal neuropathy (AMSAN) . . . . .	175
Acute pandysautonomia . . . . .	175
Addison's disease . . . . .	176
Adenohypophysitis . . . . .	176
Adrenocortical insufficiency . . . . .	177
AIH-PBC-overlap syndrome . . . . .	177
AIH-PSC overlap syndrome . . . . .	178
Alkaline phosphatase increase . . . . .	178
Aminotransferase increase . . . . .	179
Anemia . . . . .	179
Angioedema . . . . .	180
Anti-GBM nephritis . . . . .	181
Anti-NMDA receptor encephalitis . . . . .	181
Aplastic anemia . . . . .	182

Arthrogryposis multiplex congenital (AMC) . . . . .	182
Ataxia . . . . .	183
Autoimmune adrenalitis . . . . .	183
Autoimmune autonomic gangliopathy (AAG) . . . . .	183
Autoimmune blistering diseases . . . . .	185
Autoimmune cholangitis (AIC) . . . . .	185
Autoimmune cytopenia . . . . .	186
Autoimmune enteropathy (AIE) . . . . .	186
Autoimmune gastritis . . . . .	187
Autoimmune gastrointestinal dysmotility (AIGD) . . . . .	189
Autoimmune hemolytic anemia (AIHA) . . . . .	189
Autoimmune hemophilia . . . . .	190
Autoimmune hepatitis (AIH) . . . . .	191
Autoimmune hepatitis (AIH) type 1 . . . . .	194
Autoimmune hepatitis (AIH) type 2 . . . . .	195
Autoimmune hepatitis (AIH) type 3 . . . . .	195
Autoimmune hyperparathyroidism . . . . .	196
Autoimmune hypoparathyroidism . . . . .	196
Autoimmune hyperthyroidism . . . . .	197
Autoimmune hypophysitis . . . . .	198
Autoimmune liver disease . . . . .	200
Autoimmune lymphoproliferative syndrome (ALPS) . . . . .	200
Autoimmune neuropathy . . . . .	201
Autoimmune neutropenia . . . . .	201
Autoimmune pancreatitis (AIP) . . . . .	202
Autoimmune pancreatocholangitis (AIPC) . . . . .	204
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy syndrome (APECED) . . . . .	204
Autoimmune polyglandular syndrome (APS) . . . . .	205
Autoimmune polyglandular syndrome type 1 (APS-1) . . . . .	205
Autoimmune polyglandular syndrome type 2 (APS-2) . . . . .	207
Autoimmune sclerosing cholangitis (ASC) . . . . .	208
Autoimmune thrombocytopenia (AITP) . . . . .	208
Autoimmune thyroiditis (AIT) . . . . .	209
Autoimmune thyropathies (AITP) . . . . .	210
Autoimmune urticaria . . . . .	210
Bickerstaff's encephalitis . . . . .	211
Blistering dermatoses . . . . .	212
Brainstem encephalitis . . . . .	212
Bullous pemphigoid . . . . .	213
CANOMAD syndrome . . . . .	214
CAR syndrome . . . . .	214

---

CEC syndrome . . . . .	215
Celiac disease . . . . .	215
Cerebellar ataxia . . . . .	219
Cerebral folate deficiency syndrome . . . . .	220
Chagas cardiomyopathy . . . . .	220
Cholangiopathies . . . . .	221
Chronic atrophic gastritis . . . . .	221
Chronic gastrointestinal pseudo-obstruction . . . . .	221
Chronic hepatitis . . . . .	222
Chronic inflammatory demyelinating polyneuropathy (CIDP) . . . . .	222
Chronic non-purulent destructive cholangitis . . . . .	223
Chronic sensory ataxic neuropathy with anti-disialosyl antibodies . . . . .	223
Cogan syndrome . . . . .	224
Collagenous celiac disease . . . . .	224
Collagenous colitis . . . . .	225
Crohn's disease . . . . .	225
Cryptogenic hepatitis . . . . .	226
Cryptogenic liver cirrhosis . . . . .	226
Dermatitis herpetiformis (DH) . . . . .	226
Diabetes insipidus . . . . .	227
Diabetes mellitus type 1 . . . . .	228
Diabetes mellitus type 3 . . . . .	230
Dilated cardiomyopathy . . . . .	230
Down syndrome . . . . .	231
Drug induced (autoimmune) hepatitis . . . . .	231
Encephalitis . . . . .	231
Encephalomyelitis . . . . .	232
Endemic pemphigus foliaceus . . . . .	232
Endocrine orbitopathy . . . . .	233
Epidermolysis bullosa acquisita . . . . .	234
Epilepsy . . . . .	235
Evans syndrome . . . . .	235
Funicular myelosis . . . . .	235
Gamma glutamyltransferase ( $\gamma$ GT) elevation . . . . .	236
Glomerulonephritis . . . . .	236
Gluten ataxia . . . . .	238
Gluten sensitive enteropathy . . . . .	238
Goiter . . . . .	238
Goodpasture syndrome . . . . .	239
Graves' disease . . . . .	239
Guillain-Barré syndrome (GBS) . . . . .	239
Hashimoto's encephalitis . . . . .	241

Hashimoto's thyroiditis . . . . .	242
Heparin induced thrombocytopenia (HIT) . . . . .	242
Hemolytic uremic syndrome (HUS) . . . . .	242
Hyperthyroidism . . . . .	243
Hypocomplementemic urticaria-vasculitis syndrome (HUVS) . . . . .	243
Hypogonadism . . . . .	244
Hypopituitarism . . . . .	245
Hypothyroidism . . . . .	246
Idiopathic lymphadenopathy . . . . .	247
IgA nephropathy . . . . .	247
Immune cholangiopathy . . . . .	248
Immunoglobulin G4 associated cholangitis (IAC) . . . . .	248
Immunoglobulin G4 associated sclerosing disease . . . . .	248
Indeterminate colitis . . . . .	249
Inflammatory bowel disease (IBD) . . . . .	250
Infundibuloneurohypophysis . . . . .	250
Insulin autoimmune syndrome (IAS) . . . . .	251
Insulin resistance type B . . . . .	251
Interstitial pneumonia . . . . .	252
IPEX syndrome . . . . .	252
Küttner tumors . . . . .	253
LADA . . . . .	253
Lambert-Eaton myasthenic syndrome (LEMS) . . . . .	253
Lichen ruber pemphigoides . . . . .	254
Limbic encephalitis . . . . .	255
Linear IgA dermatosis (LAD) . . . . .	256
Liver cirrhosis . . . . .	257
Longitudinally extensive transverse myelitis (LETM) . . . . .	257
Lymphocytic colitis . . . . .	257
Lymphocytic gastritis . . . . .	258
Membranoproliferative glomerulonephritis (MPGN) . . . . .	258
Membranous glomerulonephritis . . . . .	259
Microscopic colitis . . . . .	260
Mikulicz syndrome . . . . .	260
Miller Fisher syndrome (MFS) . . . . .	261
Minimal change glomerulonephritis . . . . .	261
Monogenic autoimmune diseases . . . . .	261
Morvan's syndrome . . . . .	262
Motor neuropathy with monoclonal IgM gammopathy . . . . .	262
Mucous membrane pemphigoid . . . . .	263
Multifocal acquired demyelinating sensorimotor neuropathy (MADSAM)	264
Multifocal motor neuropathy (MMN) . . . . .	264

---

Multiple sclerosis . . . . .	265
Myasthenia gravis . . . . .	266
Narcolepsy . . . . .	267
Neuromyelitis optica (NMO) . . . . .	268
Neuromyotonia . . . . .	270
Neuropathies with anti-sulfatide antibodies . . . . .	271
Opsoclonus myoclonus syndrome (OMS) . . . . .	271
Optic neuritis . . . . .	272
Ord's thyroiditis . . . . .	272
Ormond's disease . . . . .	273
Osteoporosis . . . . .	273
Ovarian insufficiency . . . . .	273
Overlap syndromes of autoimmune liver diseases . . . . .	274
PANDAS . . . . .	274
Paraneoplastic autonomic neuropathies . . . . .	275
Paraneoplastic cerebellar degeneration (PCD) . . . . .	276
Paraneoplastic diseases (syndromes) . . . . .	276
Paraneoplastic encephalomyelitis (PEM) . . . . .	277
Paraneoplastic neurological diseases . . . . .	277
Paraneoplastic pemphigus . . . . .	279
Paraneoplastic retinopathy . . . . .	280
Paraproteinemic demyelinating neuropathies . . . . .	280
Partial lipodystrophy . . . . .	281
Pemphigoid . . . . .	281
Pemphigoid gestationis . . . . .	281
Pemphigus . . . . .	282
Pemphigus foliaceus . . . . .	283
Pemphigus herpetiformis . . . . .	283
Pemphigus vulgaris . . . . .	284
Pernicious anemia . . . . .	285
Polyneuropathy (PNP) . . . . .	285
Portal hypertension . . . . .	286
Postinfectious (autoimmune) hepatitis . . . . .	287
Postpartum hepatitis . . . . .	287
Postpartum thyroiditis . . . . .	288
Posttransplant nephritis . . . . .	288
Preeclampsia . . . . .	289
Premature ovarian insufficiency . . . . .	289
Primary biliary cirrhosis (PBC) . . . . .	290
Primary myxedema . . . . .	292
Primary sclerosing cholangitis (PSC) . . . . .	292
Pruritus . . . . .	294

Pulmorenal syndrome . . . . .	295
Rapid-progressive glomerulonephritis (RPGN) . . . . .	295
Rasmussen's encephalitis . . . . .	295
Retroperitoneal fibrosis . . . . .	296
Riedel's thyroiditis . . . . .	296
Sclerosing cholangitis (SC) . . . . .	296
Sclerosing sialadenitis . . . . .	297
Sensorineural hearing loss . . . . .	297
Sicca symptoms . . . . .	297
Stiff person syndrome (SPS) . . . . .	297
Subacute cerebellar degeneration . . . . .	298
Subacute sensory neuropathy (SSN) . . . . .	298
Sudeck's disease . . . . .	299
Sydenham chorea . . . . .	299
Sympathetic ophthalmia . . . . .	300
Thrombotic microangiopathy . . . . .	300
Thrombotic thrombocytopenic purpura (TTP) . . . . .	301
Transverse myelitis . . . . .	301
Tubulointerstitial nephritis . . . . .	302
Ulcerative colitis . . . . .	302
Vitiligo . . . . .	303